Company news: Boehringer Ingelheim, GlaxoSmithKline

Share this article:
Boehringer Ingelheim's foray into oncology meds now includes a five-year collaboration agreement with personalized medicine specialist Horizon Discovery. The agreement gives Boehringer access to its Discovery Toolbox, which will profile the drug maker's compounds, and Genesis, Horizon's genome editing technology to help develop human isogenic disease model cells. Horizon said the technology will help develop “high quality cell lines” that model disease-causing mutations.

Months after its Human Genome Sciences buy, GlaxoSmithKline has submitted a BLA for albiglutide, a pipeline diabetes 2 therapy. GSK gained full ownership of the therapy with its HGS acquisition, along with ownership of Benlysta and darapladib. The experimental drug, which is being developed as a weekly shot, is a GLP-1 agonist, much like Amylin's weekly Bydureon.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.